These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6514699)

  • 21. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
    Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
    Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pyridoxine metabolism in pulmonary tuberculosis patients under rifampicin therapy in combination with isoniazid].
    Baĭramaliev G; Krasheninnikova MA; Kolosovskaia VP; Chukanov VI
    Probl Tuberk; 1982 Jan; (1):58-62. PubMed ID: 7058194
    [No Abstract]   [Full Text] [Related]  

  • 23. [Early results of treatment of patients with chronic pulmonary tuberculosis with rifampicin].
    Böszörmenyi M
    Gruzlica; 1974 May; 42(5):407-10. PubMed ID: 4464228
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapeutic possibilities of inhalation of rifampicin with dimexide in phthisiopulmonology].
    Gorbach IN; Samtsov VS
    Probl Tuberk; 1991; (3):34-6. PubMed ID: 1871090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Short-course chemotherapy for pulmonary tuberculosis. 1. Clinical effect of RFP, INH and EB regimen for 9 months in the original treatment for pulmonary tuberculosis (author's transl)].
    Oda T
    Kekkaku; 1980 Jul; 55(7):331-9. PubMed ID: 7206413
    [No Abstract]   [Full Text] [Related]  

  • 26. [Short-term intensive therapy of destructive pulmonary tuberculosis].
    Bondarev IM; Zhigalina LI; Kunichan AD
    Probl Tuberk; 1980 Dec; (12):57-9. PubMed ID: 7220536
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical effects of rifampicin applied every other day for severe cavitary pulmonary tuberculosis].
    Hashimoto T; Takahashi S; Kasai K; Tamura M; Yamada M
    Kekkaku; 1972 Aug; 47(8):273-7. PubMed ID: 4660855
    [No Abstract]   [Full Text] [Related]  

  • 28. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of blood concentration of rifampicin between administration before and after breakfast].
    Tsukamura M; Yokouchi J; Miwa T; Koike K
    Kekkaku; 1972 Apr; 47(4):69-73. PubMed ID: 5073928
    [No Abstract]   [Full Text] [Related]  

  • 31. [Results of treatment of newly detected pulmonary tuberculosis with rifampin combined with isoniazid and ethambutol].
    Szymański A; Walecki J; Czaplińska-Jóźwiak E; Kuczborska Z; Gaik A; Bilczak Z; Swiatnicka I; Swica T; Zdawski T
    Pneumonol Pol; 1980 Nov; 48(11):669-74. PubMed ID: 7255207
    [No Abstract]   [Full Text] [Related]  

  • 32. [Intermittent administration of rifadine in destructive forms of pulmonary tuberculosis].
    Sobolevskaia LI; Korobko GV
    Vrach Delo; 1975 Apr; (4):60-2. PubMed ID: 1216820
    [No Abstract]   [Full Text] [Related]  

  • 33. [Experience with endobronchial and local use of rifampicin in tuberculosis].
    Abdurashitova MV; Stoianovskiĭ EA; Fok AIa
    Probl Tuberk; 1976 Jan; (l):35-8. PubMed ID: 995905
    [No Abstract]   [Full Text] [Related]  

  • 34. [L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis].
    Khomenko AG; Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE
    Probl Tuberk; 1980 Feb; (2):18-23. PubMed ID: 6769110
    [No Abstract]   [Full Text] [Related]  

  • 35. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinico-immunological substantiation of the use of rifampicin in the combined therapy of adults and adolescents with destructive pulmonary tuberculosis].
    Chernushenko EF; Kogosova LS; Il'nitskiĭ IG; Petrashenko AI; Goncharova SI
    Probl Tuberk; 1989; (7):39-43. PubMed ID: 2798385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rifampicin in the treatment of newly detected adolescent pulmonary tuberculosis patients].
    Ganiev KG; Esanbaev DE; Kirina SB
    Probl Tuberk; 1983 May; (5):42-6. PubMed ID: 6866983
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparison of therapeutic effects of rifampicin 450 mg daily and 600 mg three times weekly on the previously treated pulmonary tuberculosis patients].
    Yamamoto M; Mizutani A; Nakamura H; Hirose H; Nagata A
    Kekkaku; 1973 May; 48(5):197-202. PubMed ID: 4732658
    [No Abstract]   [Full Text] [Related]  

  • 39. [Possibilities and limitations of long-term treatment with rifampicin infusion in tubercular disease].
    Rosetti L; Serra A; Arba GV
    G Ital Chemioter; 1982; 29(2):125-32. PubMed ID: 7186465
    [No Abstract]   [Full Text] [Related]  

  • 40. Rifampicin-aluminium antacid interaction.
    Gupta PR; Mehta YR; Gupta ML; Sharma TN; Jain D; Gupta RB
    J Assoc Physicians India; 1988 Jun; 36(6):363-4. PubMed ID: 3182711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.